Top

Published in:

01-04-2011 | Epidemiology

Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis

Authors: Chao Shen, Haiming Sun, Donglin Sun, Lidan Xu, Xuelong Zhang, An Liu, Xueyuan Jia, Jing Bai, Feng Chen, Yang Yu, Yan Jin, Jingcui Yu, Songbin Fu

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Abstract

We conducted a meta-analysis to assess the association between tumor necrosis factor-alpha (TNF-alpha) gene TNFA −308 (G>A), TNFA −238 (G>A), TNFA −857 (C>T), TNFA −863 (C>A), TNFA −1031 (T>C), TNFA −1210 (A>T) polymorphisms and breast cancer(BC) susceptibility. We also performed subgroup analyses based on ethnicity (Caucasian, Asian, and African). An extensive search was performed to identify all case–control studies investigating such association. Thirteen eligible studies, including 10,236 BC patients and 13,143 controls, were identified. No significant association was observed in all genotypes in worldwide populations, but stratification by ethnicity indicated that the TNFA −308 A allele was associated with a decreased risk of BC compared with the G allele in Caucasian individuals (OR = 0.927, 95%CI = 0.879–0.978). Similar results were obtained when the A/A +A/G genotype was compared with the G/G genotype. In addition, meta-analysis results indicated that the A/A genotype of TNFA −308 was a risk factor for BC in African (A/A vs. G/G OR = 4.085 95%CI = 1.460–11.425; A/A vs. G/A OR = 4.861 95%CI = 1.746–13.527; A/A vs. G/A + G/G OR = 4.246 95%CI = 1.551–11.625), but not in Caucasian or Asian individuals. In conclusion, the results of this meta-analysis indicate that the TNFA −308 A allele may be an important protective factor for BC in European individuals, but it is not likely to confer susceptibility to BC in worldwide populations. In addition, the AA genotype of TNFA −308 may be a risk factor for BC in African individuals. Besides, other polymorphisms were not associated with BC susceptibility.

Colditz GA, Sellers TA, Trapido E (2006) Epidemiology—identifying the causes and preventability of cancer? Nat Rev Cancer 6(1):75–83PubMedCrossRef

Welch DR, Steeg PS, Rinker-Schaeffer CW (2000) Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res 2(6):408–416PubMedCrossRef

Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72(9):3666–3670PubMedCrossRef

Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334(26):1717–1725PubMedCrossRef

Strieter RM, Kunkel SL, Bone RC (1993) Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 21(10 Suppl):S447–S463PubMedCrossRef

Ardizzoia A, Lissoni P, Brivio F, Tisi E, Perego MS, Grassi MG, Pittalis S, Crispino S, Barni S, Tancini G (1992) Tumor necrosis factor in solid tumors: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 6(3):103–107PubMed

Raabe T, Bukrinsky M, Currie RA (1998) Relative contribution of transcription and translation to the induction of tumor necrosis factor-alpha by lipopolysaccharide. J Biol Chem 273(2):974–980PubMedCrossRef

Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, Louis R et al (1998) Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 113(3):401–406PubMedCrossRef

Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, Itoh K (1998) Polymorphism of the 5’-flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens 51(6):605–612PubMedCrossRef

10.

Kohaar I, Tiwari P, Kumar R, Nasare V, Thakur N, Das BC, Bharadwaj M (2009) Association of single nucleotide polymorphisms (SNPs) in TNF-LTA locus with breast cancer risk in Indian population. Breast Cancer Res Treat 114(2):347–355PubMedCrossRef

11.

Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, Chouchane L (2001) Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 91(4):672–678PubMedCrossRef

12.

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed

13.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188PubMedCrossRef

14.

Munafo MR, Clark TG, Flint J (2004) Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res 129(1):39–44PubMedCrossRef

15.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101PubMedCrossRef

16.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMed

17.

MARIE-GENICA Consortium (2009) Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women. Breast Cancer Res Treat 120(3):727–736

18.

Azmy IA, Balasubramanian SP, Wilson AG, Stephenson TJ, Cox A, Brown NJ, Reed MW (2004) Role of tumour necrosis factor gene polymorphisms (−308 and −238) in breast cancer susceptibility and severity. Breast Cancer Res 6(4):R395–R400PubMedCrossRef

19.

Chouchane L, Ahmed SB, Baccouche S, Remadi S (1997) Polymorphism in the tumor necrosis factor-alpha promotor region and in the heat shock protein 70 genes associated with malignant tumors. Cancer 80(8):1489–1496PubMedCrossRef

20.

Gallicchio L, McSorley MA, Newschaffer CJ, Huang HY, Thuita LW, Hoffman SC, Helzlsouer KJ (2007) Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev 31(2):95–101PubMedCrossRef

21.

Gaudet MM, Egan KM, Lissowska J, Newcomb PA, Brinton LA, Titus-Ernstoff L, Yeager M, Chanock S, Welch R, Peplonska B et al (2007) Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk. Hum Genet 121(3–4):483–490PubMedCrossRef

22.

Giordani L, Bruzzi P, Lasalandra C, Quaranta M, Schittulli F, Della Ragione F, Iolascon A (2003) Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem 49(10):1664–1667PubMedCrossRef

23.

Kamali-Sarvestani E, Merat A, Talei AR (2005) Polymorphism in the genes of alpha and beta tumor necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett 223(1):113–119PubMedCrossRef

24.

Ostashkin AS, Malivanova TF, Iurchenko VA, Mazurenko NN (2008) Tumor necrosis factor gene polymorphisms in breast cancer patients. Genetika 44(9):1275–1280PubMed

25.

Park KS, Mok JW, Ko HE, Tokunaga K, Lee MH (2002) Polymorphisms of tumour necrosis factors A and B in breast cancer. Eur J Immunogenet 29(1):7–10PubMedCrossRef

26.

Scola L, Vaglica M, Crivello A, Palmeri L, Forte GI, Macaluso MC, Giacalone A, Di Noto L, Bongiovanni A, Raimondi C et al (2006) Cytokine gene polymorphisms and breast cancer susceptibility. Ann N Y Acad Sci 1089:104–109PubMedCrossRef

27.

Sirotkovic-Skerlev M, Cacev T, Krizanac S, Kulic A, Pavelic K, Kapitanovic S (2007) TNF alpha promoter polymorphisms analysis in benign and malignant breast lesions. Exp Mol Pathol 83(1):54–58PubMedCrossRef

28.

Kopreski MS, Lipton A, Harvey HA, Kumar R (1996) Growth inhibition of breast cancer cell lines by combinations of anti-P185HER2 monoclonal antibody and cytokines. Anticancer Res 16(1):433–436PubMed

29.

Pagliacci MC, Fumi G, Migliorati G, Grignani F, Riccardi C, Nicoletti I (1993) Cytostatic and cytotoxic effects of tumor necrosis factor alpha on MCF-7 human breast tumor cells are differently inhibited by glucocorticoid hormones. Lymphokine Cytokine Res 12(6):439–447PubMed

30.

Cai Z, Stancou R, Korner M, Chouaib S (1996) Impairment of Fas-antigen expression in adriamycin-resistant but not TNF-resistant MCF7 tumor cells. Int J Cancer 68(4):535–546PubMedCrossRef

31.

Hagihara M, Shimura T, Sato K, Genga K, Suzuki M, Tsuji K (1995) HLA and tumor necrosis factor beta gene polymorphisms in Okinawa lung cancer patients: comparative study with mainland Japan lung cancer patients. Hum Immunol 43(2):95–100PubMedCrossRef

32.

Messer G, Spengler U, Jung MC, Honold G, Blomer K, Pape GR, Riethmuller G, Weiss EH (1991) Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 173(1):209–219PubMedCrossRef

33.

Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, Sato H, Hori M, Nakamura Y, Tanaka T (2002) Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 32(4):650–654PubMedCrossRef

34.

Soga Y, Nishimura F, Ohyama H, Maeda H, Takashiba S, Murayama Y (2003) Tumor necrosis factor-alpha gene (TNF-alpha) −1031/−863, −857 single-nucleotide polymorphisms (SNPs) are associated with severe adult periodontitis in Japanese. J Clin Periodontol 30(6):524–531PubMedCrossRef

35.

Kaijzel EL, Bayley JP, van Krugten MV, Smith L, van de Linde P, Bakker AM, Breedveld FC, Huizinga TW, Verweij CL (2001) Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun 2(3):135–144PubMedCrossRef

36.

Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, Hartl D, Yunis EJ, Goldfeld AE (1998) Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens 52(4):359–367PubMedCrossRef

Title: Polymorphisms of tumor necrosis factor-alpha and breast cancer risk: a meta-analysis
Authors: Chao Shen
Haiming Sun
Donglin Sun
Lidan Xu
Xuelong Zhang
An Liu
Xueyuan Jia
Jing Bai
Feng Chen
Yang Yu
Yan Jin
Jingcui Yu
Songbin Fu
Publication date: 01-04-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1184-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Mediator of DNA damage checkpoint protein 1 (MDC1) expression as a prognostic marker for nodal recurrence in early-stage breast cancer patients treated with breast-conserving surgery and radiation therapy

Validating the meta-analytical results on MDM2, CASP8, XRCC3 polymorphisms and breast cancer risk: examination of Hardy–Weinberg Equilibrium

Unincluded subjects need to be included for concerning the real association between TNFa-308 G/A polymorphism and cancer susceptibility

A combined analysis of genome-wide association studies in breast cancer

Young age, increased tumor proliferation and FOXM1 expression predict early metastatic relapse only for endocrine-dependent breast cancers

Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer